| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS10019173 | HBV | ENSG00000120907.18 | protein_coding | ADRA1A | No | No | 148 | B0ZBD3 P35348 |
| TVIS10019323 | HBV | ENSG00000120907.18 | protein_coding | ADRA1A | No | No | 148 | B0ZBD3 P35348 |
| TVIS10031044 | HBV | ENSG00000120907.18 | protein_coding | ADRA1A | No | No | 148 | B0ZBD3 P35348 |
| TVIS10025139 | HBV | ENSG00000120907.18 | protein_coding | ADRA1A | No | No | 148 | B0ZBD3 P35348 |
| TVIS10020261 | HBV | ENSG00000120907.18 | protein_coding | ADRA1A | No | No | 148 | B0ZBD3 P35348 |
| TVIS10040464 | HBV | ENSG00000120907.18 | protein_coding | ADRA1A | No | No | 148 | B0ZBD3 P35348 |
| TVIS20001928 | HPV | ENSG00000120907.18 | protein_coding | ADRA1A | No | No | 148 | B0ZBD3 P35348 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | ADRA1A |
|---|---|
| DrugBank ID | DB00590 |
| Drug Name | Doxazosin |
| Target ID | BE0000501 |
| UniProt ID | P35348 |
| Regulation Type | antagonist |
| PubMed IDs | 15573147; 8736427; 14767264; 9205965; 16225542; 19002123; 17070143; 10393471; 18304211; 9223558 |
| Citations | Yono M, Foster HE Jr, Shin D, Takahashi W, Pouresmail M, Latifpour J: Doxazosin-induced up-regulation of alpha 1A-adrenoceptor mRNA in the rat lower urinary tract. Can J Physiol Pharmacol. 2004 Oct;82(10):872-8.@@Michel MC, Grubbel B, Taguchi K, Verfurth F, Otto T, Kropfl D: Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996 Feb;16(1):21-8.@@Roehrborn CG, Schwinn DA: Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol. 2004 Mar;171(3):1029-35.@@Ishizuka O, Pandita RK, Mattiasson A, Steers WD, Andersson KE: Stimulation of bladder activity by volume, L-dopa and capsaicin in normal conscious rats--effects of spinal alpha 1-adrenoceptor blockade. Naunyn Schmiedebergs Arch Pharmacol. 1997 Jun;355(6):787-93.@@Bae JH, Jung PB, Lee JG: The effects of alpha-adrenoceptor antagonists on the urethral perfusion pressure of the female rat. BJU Int. 2005 Nov;96(7):1131-5.@@Greco KA, McVary KT: The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. doi: 10.1038/ijir.2008.51.@@Shannon R, Chaudhry M: Effect of alpha1-adrenergic receptors in cardiac pathophysiology. Am Heart J. 2006 Nov;152(5):842-50.@@Martin DJ: Preclinical pharmacology of alpha1-adrenoceptor antagonists. Eur Urol. 1999;36 Suppl 1:35-41; discussion 65.@@Schwinn DA, Roehrborn CG: Alpha1-adrenoceptor subtypes and lower urinary tract symptoms. Int J Urol. 2008 Mar;15(3):193-9. doi: 10.1111/j.1442-2042.2007.01956.x.@@Martin DJ, Lluel P, Guillot E, Coste A, Jammes D, Angel I: Comparative alpha-1 adrenoceptor subtype selectivity and functional uroselectivity of alpha-1 adrenoceptor antagonists. J Pharmacol Exp Ther. 1997 Jul;282(1):228-35. |
| Groups | Approved |
| Direct Classification | N-arylpiperazines |
| SMILES | COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1 |
| Pathways | |
| PharmGKB | PA449407 |
| ChEMBL | CHEMBL707 |
